FDA Gov - Search News

FDA panel rejects only 1 peptide

FDA panel supports broadening access to peptides popular on the gray market

A panel of advisers to the Food and Drug Administration is recommending that the federal government green-light the production of two popular peptides by specialized pharmacies in the U.S.

· 1d

FDA panel gives nod to six controversial peptides

· 1d

FDA Committee Votes on These 7 Peptides

· 1d

FDA Advisers Dismiss Safety Warnings, Back Four Peptide Treatments

The votes are nonbinding, but they amount to a rebuke of the FDA’s own scientists who said the drugs have not been studied enough to know whether they are safe or effective, reports The New York Times...

· 1d

F.D.A. Panel’s Vote on Peptides Raises Concerns About a Prescribing Boom

· 1d

US health panel loosens restrictions for controversial peptides popular online

· 1d

FDA Panel Clears the Way for 6 Banned Peptides. Here’s What They’re Claimed to Do

Over the span of two days, the panel said yes in a majority vote to six of these peptides being stricken from the Category 2 list: BPC-157, KPV, TB-500, MOTs-C, epitalon, and semax.

STAT · 1d

FDA advisory panel narrowly rejects compounding of one peptide, back another

· 1d

FDA panel backs peptide drug beloved Joe Rogan after RFK Jr shows support for injections

CNBC

FDA declines to issue specific guidance on health programs' foreign drug imports

The Food and Drug Administration responded to a health policy group requesting clear enforcement of alternative funding programs, or AFPs. The agency reiterated its regulation against the foreign importation of drugs, but declined to issue specific guidance.

Medical Xpress

FDA unveils drugs to receive expedited review in support of 'national priorities'

The Food and Drug Administration on Thursday announced the first round of experimental drugs that will receive drastically expedited reviews at the agency, part of an effort to prioritize medicines the Trump administration deems as "supporting U.S ...

Psychiatry Advisor

FDA Drug Approval Decisions Expected in August 2026

Treatments for fibrodysplasia ossificans progressiva, gastroenteropancreatic neuroendocrine tumors, HIV, influenza, and multiple myeloma are under review.

CNBC

FDA proposes new system for approving customized drugs and therapies for rare diseases

Federal health officials on Monday laid out a proposal to spur development of customized treatments for patients with hard-to-treat diseases, including for rare genetic conditions that the pharmaceutical industry has long considered unprofitable.

Ars Technica

FDA advisors unanimously vote to approve Moderna’s mRNA after agency drama

Independent advisors for the Food and Drug Administration on Friday voted 9–0 in support of approving Moderna’s seasonal mRNA flu vaccine, which a Trump appointee at the agency initially tried to block from even being reviewed. In an all-day meeting ...